PR Newswire
Fingerpaint Group Elevates Ops and Strategy Leaders to Boost Enterprise Marketing Platform, announcing veteran hires that aim to fuse AI-driven operations with enterprise‑wide strategic insight across its integrated marketing, medical, branding, and market‑access solutions.
Fingerpaint Group, the fast‑growing independent agency that serves the majority of the world’s top pharmaceutical brands, disclosed two senior appointments on May 5, 2026. Stephanie Spicer steps into the newly created role of Group Managing Director, Operations, while Nick Megjugorac assumes the post of Chief Strategy Officer. Both executives will report directly to Group President Mark Willmann, signaling a deliberate push to tighten the company’s operational backbone and strategic coherence across its multi‑solution platform.
Spicer’s nine‑year tenure at Fingerpaint has been defined by building the repeatable processes that allowed the Marketing Services unit to scale without sacrificing quality. In her expanded remit, she will extend that framework to the entire organization, embedding generative‑AI tools into workflow orchestration, data hygiene, and resource allocation. “The job hasn’t changed—clear process, clear ownership, and teams focused on the work and the clients,” Spicer said. “What’s different now is the space AI creates to rethink how we work entirely.” Her mandate is to turn AI from a supplemental capability into a core operating layer that frees creative and account teams to focus on high‑value client work.
Megjugorac, a strategic architect of Fingerpaint’s commercial positioning for eight years, will now steward a unified strategic vision that cuts across marketing, medical, branding, and market‑access. “Strategy only works when it is well‑informed,” he explained. “A unified strategic point of view… means our partners get a comprehensive and well‑rounded perspective, and solutions that hold up under pressure.” By centralizing market intelligence, competitive analysis, and client‑centric road‑mapping, Megjugorac’s office is expected to deliver faster go‑to‑market cycles and more consistent messaging across the agency’s four solution pillars.
The dual hires come at a moment when Fingerpaint has been recognized as Med Ad News’ Network of the Year and has closed 2025 with record revenue. The firm now works with 95 % of the top 20 global pharma companies, and two‑thirds of those clients engage multiple solutions on the platform. In a market where Gartner predicts that AI‑enabled marketing platforms will capture 30 % of global spend by 2028, Fingerpaint’s leadership shuffle appears designed to capture a larger slice of that growth.
From an industry standpoint, the appointments underscore a broader shift: integrated agencies are moving from siloed service offerings to platform‑centric models that promise end‑to‑end data flow, real‑time optimization, and unified measurement. Competing networks such as WPP’s GroupM and Publicis’ Vivaki have recently launched AI‑first operating systems, but Fingerpaint’s approach differs by coupling AI with a newly formalized chief strategy function, a structure that few rivals have publicly adopted.
Enterprise marketing teams stand to benefit from the tighter alignment. With AI‑augmented ops, campaign planning cycles could shrink by up to 25 %—a figure echoed in a recent Forrester study on AI‑driven workflow automation. Meanwhile, a single strategic voice reduces the risk of fragmented brand messaging, a common pain point for pharma marketers juggling compliance, medical review, and commercial goals.
Willmann summed up the strategic intent: “We have the platform, the clients, and the momentum. What Steph and Nick bring is the organizational architecture to make sure all of it works together.” If the new structure delivers on its promise, Fingerpaint could set a new benchmark for how integrated agencies leverage AI and strategic centralization to serve data‑rich, highly regulated industries.
Operational Excellence Powered by AI
Spicer’s mandate focuses on turning generative‑AI tools into process enablers, from automated brief generation to predictive resource scheduling. By standardizing rhythm and cadence across all solution groups, the firm hopes to reduce internal friction and improve billable efficiency.
Strategic Cohesion Across Solutions
Megjugorac’s role consolidates market insights, competitive intelligence, and client objectives into a single strategic engine. This should streamline cross‑solution collaboration, ensuring that a brand’s medical messaging aligns with its market‑access positioning and creative execution.
Scaling Within a Competitive Landscape
Fingerpaint’s record revenue and near‑ubiquitous presence among top pharma firms position it to outpace rivals that still operate with fragmented leadership structures. The AI‑first operational model may also help the agency meet the rising demand for real‑time attribution and compliance reporting.
Market Landscape
The ad‑tech ecosystem is in the midst of an AI‑driven transformation. IDC forecasts that worldwide AI‑enhanced marketing technology spend will exceed $120 billion by 2027, driven by demand for faster activation and more granular measurement. In parallel, privacy regulations such as the EU’s Digital Services Act and the U.S. CCPA‑derived state laws are forcing agencies to embed compliance checks directly into their tech stacks. Fingerpaint’s dual focus on AI‑enabled operations and unified strategy positions it to navigate both the efficiency push and the compliance imperative.
Competitors are racing to replicate similar structures. GroupM’s “Unified Media Platform” integrates data, analytics, and activation under a single roof, while Publicis’ “One Brand” initiative seeks to harmonize creative and media planning. However, few have announced a dedicated chief strategy officer whose remit spans all solution silos. This could give Fingerpaint a first‑mover advantage in delivering consistent, data‑backed narratives for pharma clients who must balance scientific rigor with commercial appeal.
Top Insights
- AI‑first ops cut campaign lead times: Fingerpaint aims to reduce planning cycles by up to 25 % through AI‑driven workflow automation, echoing Forrester’s findings on efficiency gains.
- Unified strategy mitigates brand fragmentation: A single strategic office aligns medical, branding, and market‑access messages, addressing a common compliance pain point in pharma advertising.
- Platform integration drives market share: With 95 % of top pharma firms as clients, Fingerpaint’s consolidated platform could capture a larger slice of the projected $120 B AI‑ad‑tech market by 2027.
- Competitive edge over siloed rivals: The combination of an AI‑enabled operations layer and a chief strategy role is rare among large agency networks, offering a differentiated value proposition.
- Regulatory readiness built in: Embedding compliance into the AI workflow ensures that campaigns meet GDPR, DSA, and emerging U.S. privacy standards without manual bottlenecks.
Get in touch with our Adtech experts
BusinessWire
